Evidence map›Paper›PMID 29561842›Full record

ArticlePLoS neglected tropical diseases2018

Antimony susceptibility of Leishmania isolates collected over a 30-year period in Algeria.

Naouel Eddaikra, Khatima Ait-Oudhia, Ihcen Kherrachi, Bruno Oury, Farida Moulti-Mati, Razika Benikhlef, Zoubir Harrat, Denis Sereno

Abstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Review
  2. Detection ofMicroorganisms · 2025
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. MPLA and AddaVaxMicroorganisms · 2021
    Article
  15. Article
  16. Article
  17. Article
  18. Updates on Geographical Dispersion ofPathogens (Basel, Switzerland) · 2021
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Naouel EddaikraLaboratory of Eco-epidemiology Parasitic Population Genetics, Pasteur Institute of Algiers, Algiers, Algeria.
Khatima Ait-OudhiaNational Veterinary School, Algiers, Algeria.
Ihcen KherrachiLaboratory of Eco-epidemiology Parasitic Population Genetics, Pasteur Institute of Algiers, Algiers, Algeria.
Bruno OuryIRD, Univ Montpellier, MIVEGEC, Montpellier, France.
Farida Moulti-MatiLaboratory of Analytic Biochemistry and Biotechnology, Univ Mouloud Mammeri, Tizi Ouzou, Algeria.
Razika BenikhlefLaboratory of Eco-epidemiology Parasitic Population Genetics, Pasteur Institute of Algiers, Algiers, Algeria.
Zoubir HarratLaboratory of Eco-epidemiology Parasitic Population Genetics, Pasteur Institute of Algiers, Algiers, Algeria.
Denis SerenoIRD, Univ Montpellier, MIVEGEC, Montpellier, France.ORCID 0000-0002-0034-9291

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn Algeria, the treatment of visceral and cutaneous leishmanioses (VL and CL) has been and continues to be based on antimony-containing drugs. It is suspected that high drug selective pressure might favor the emergence of chemoresistant parasites. Although treatment failure is frequently reported during antimonial therapy of both CL and VL, antimonial resistance has never been thoroughly investigated in Algeria. Determining the level of antimonial susceptibility, amongst Leishmania transmitted in Algeria, is of great importance for the development of public health policies. METHODOLOGY/PRINCIPAL

findingsWithin the framework of the knowledge about the epidemiology of VL and CL amassed during the last 30 years, we sampled Leishmania isolates to determine their susceptibility to antimony. We analyzed a total of 106 isolates including 88 isolates collected between 1976 and 2013 in Algeria from humans, dogs, rodents, and phlebotomines and 18 collected from dogs in France. All the Algerian isolates were collected in 14 localities where leishmaniasis is endemic. The 50% inhibitory concentrations (IC50) of potassium antimony tartrate (the trivalent form of antimony, Sb(III)) and sodium stibogluconate (the pentavalent form of antimony, Sb(V)) were determined in promastigotes and intramacrophage amastigotes, respectively. The epidemiological cutoff (ECOFF) that allowed us to differentiate between Leishmania species causing cutaneous or visceral leishmaniases that were susceptible (S+) or insusceptible (S-) to the trivalent form of antimony was determined. The computed IC50 cutoff values were 23.83 μg/mL and 15.91 μg/mL for VL and CL, respectively. We report a trend of increasing antimony susceptibility in VL isolates during the 30-year period. In contrast, an increase in the frequency of S- phenotypes in isolates causing CL was observed during the same period. In our study, the emergence of S- phenotypes correlates with the inclusion of L. killicki (syn: L. tropica) isolates that cause cutaneous leishmaniasis and that have emerged in Algeria during the last decade. CONCLUSION/SIGNIFICANCE: Our results provide insight into the spatiotemporal dynamics of Leishmania antimony susceptibility in Algeria. We highlight the need for the future implementation of an effective methodology to determine the antimony susceptibility status of Leishmania isolates to detect the emergence of and prevent the dissemination of drug-resistant strains.

Indexed as

AlgeriaAnimalsAntimonyAntimony Sodium GluconateAntiprotozoal AgentsDogsDrug ResistanceHumansInhibitory Concentration 50LeishmaniaLeishmaniasis, CutaneousLeishmaniasis, VisceralPsychodidaeRodentiaAntimonyAntimony Sodium GluconateAntiprotozoal Agents

Identifiers

PMID29561842
PMCPMC5889277

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.